Does BUROSUMAB Cause Product use in unapproved indication? 22 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 22 reports of Product use in unapproved indication have been filed in association with BUROSUMAB (CRYSVITA). This represents 3.3% of all adverse event reports for BUROSUMAB.
22
Reports of Product use in unapproved indication with BUROSUMAB
3.3%
of all BUROSUMAB reports
0
Deaths
3
Hospitalizations
How Dangerous Is Product use in unapproved indication From BUROSUMAB?
Of the 22 reports, 3 (13.6%) required hospitalization.
Is Product use in unapproved indication Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BUROSUMAB. However, 22 reports have been filed with the FAERS database.
What Other Side Effects Does BUROSUMAB Cause?
Product dose omission issue (124)
Pain (69)
Inappropriate schedule of product administration (64)
Arthralgia (59)
Therapy interrupted (57)
Blood phosphorus decreased (53)
Pain in extremity (50)
Restless legs syndrome (49)
Back pain (35)
Fatigue (34)
What Other Drugs Cause Product use in unapproved indication?
DUPILUMAB (33,452)
DICLOFENAC (12,197)
METHOTREXATE (8,930)
PREDNISONE (7,625)
RITUXIMAB (7,519)
MYCOPHENOLATE MOFETIL (5,910)
ACETAMINOPHEN (5,819)
CYCLOPHOSPHAMIDE (5,750)
RISPERIDONE (5,551)
TACROLIMUS (5,057)
Which BUROSUMAB Alternatives Have Lower Product use in unapproved indication Risk?
BUROSUMAB vs BUROSUMAB-TWZA
BUROSUMAB vs BUSPIRONE
BUROSUMAB vs BUSULFAN
BUROSUMAB vs BUSULFEX
BUROSUMAB vs BUTALBITAL